All That Glitters: Bristol/Merck's Muraglitazar Will Be Pargluva
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies release Phase II and III data for the dual PPAR agonist at the American Diabetes Association annual meeting. Pargluva showed a statistically significant difference in reduction of A1C levels versus Lilly/Takeda's Actos in type 2 diabetes patients in the 24-week Phase III trial.